The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $231.12, a high ...

KeyBanc Capital Markets adjusted its price target on Inspire Medical Systems (NYSE:INSP) shares, lowering it to $234 from $236, while maintaining an Overweight rating on the stock. The revision ...

In a report released today, Brett Fishbin from KeyBanc maintained a Buy rating on Inspire Medical Systems (INSP – Research Report), with a ...

Stifel analysts adjusted their outlook on Inspire Medical Systems (NYSE:INSP), reducing the price target to $190 from the previous $200 while maintaining a Hold rating on the stock. The revision ...

The global sleep apnea implants market is expected to grow from USD 317.1 million in 2023 to USD 1,158.1 million by 2033, at ...

Wells Fargo analyst Larry Biegelsen maintained a Hold rating on Inspire Medical Systems (INSP – Research Report) yesterday and set a price ...

Awareness of sleep apnea and its relatively common and effective treatment has grown over the past three decades.

Inspire Medical Systems shows improving price performance, earning an upgrade to its IBD Relative Strength Rating from 72 to 81. Jim Cramer Predicts Palantir Buying Surge Tonight After Morgan ...

Inspire Medical Systems, Inc. (NYSE:INSP) is a medical technology company, focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea.

Following weight loss, these patients could become more likely to benefit from Inspire. All in all, the population of people diagnosed with sleep apnea is very large, and we believe Inspire is ...

Her work has appeared in Women's Health, SELF, Prevention, The Washington Post, and more. Sleep apnea impacts about 30 million American adults, making it a common sleep disorder. But while plenty ...

The Food and Drug Administration (FDA) on Dec. 20 approved the obesity medication Zepbound (tirzepatide) as the first pharmaceutical treatment for moderate-to-severe obstructive sleep apnea (OSA) in ...